| Literature DB >> 33747690 |
Alexandra I Naides1, Jerette J Schultz1, Nikita O Shulzhenko1, Jonathan D Keith1,2.
Abstract
Chest masculinization for gender affirmation is the removal of breast tissue and excess skin, often with repositioning of the nipple areola complexes to achieve a male-appearing chest. A double-incision technique with free nipple grafting (FNG) is the preferred method for trans men with large, ptotic breasts. The authors present the outcomes of 72 consecutive chest masculinization cases using this technique.Entities:
Year: 2021 PMID: 33747690 PMCID: PMC7963498 DOI: 10.1097/GOX.0000000000003459
Source DB: PubMed Journal: Plast Reconstr Surg Glob Open ISSN: 2169-7574
Fig. 1.Preoperative markings.
Fig. 2.Elevation of superior flap up to clavicle.
Fig. 3.En bloc tissue removal.
Video 1.Nipple areolar complex placement technique. Video 1 from “Chest Masculinization for Gender Affirmation: Analysis of Technique and Outcomes in 72 Double Incision Chest Contouring Procedures with Free Nipple Grafting”
Figure 4.Pre- and postoperative photographs. A, Preoperative photograph of patient with grade I ptosis. B, Postoperative result.
Figure 5.Pre- and postoperative photographs. A, Preoperative photograph of patient with grade III ptosis. B, Postoperative result.
Patient Demographics and Operative Details (n = 72)
| Age in years, mean (SD; range) | 26.5 (±7.9; 16–56) |
| BMI, mean (SD; range) | 28.5 (±6.8; 15.7–46.8) |
| Race, % | |
| White | 52.8% |
| Black | 30.6% |
| Hispanic | 5.6% |
| Asian | 1.4% |
| Other or mixed | 9.7% |
| Binding | |
| History of binding, % | 55.6% |
| Length of binding in months, mean (SD; range) | 47.7 (±38.5; 3–120) |
| Testosterone use | |
| History of use, % | 79.2% |
| Length of use in months, mean (SD; range) | 22.9 (±16.6; 3–72) |
| Smoking history | |
| History of use, % | 29.2% |
| Comorbidities | |
| Hypertension | 2.8% |
| Diabetes | 1.4% |
| Hyperlipidemia | 4.2% |
| Psychiatric diagnosis | 29.2% |
| Operative details | |
| Average weight per breast in grams (SD; range) | 648 (±426.9; 118–2284) |
| Average operative time in minutes (SD; range) | 156 (±35.1; 71–240) |
Complications
| Major complications | n = 72 (%) |
| Hematoma (return to OR) | 3 (4.2) |
| Hematoma (IR drain) | 1 (1.4) |
| Abscess | 1 (1.4) |
| Postoperative atelectasis | 1 (1.4) |
| Minor complications | n = 72 (%) |
| Seroma | 3 (4.2) |
| Delayed wound healing | 1 (1.4) |
| Superficial thrombophlebitis | 1 (1.4) |
| Dog-ear | 6 (8.3) |
| Hypertrophic scarring | 4 (5.6) |
| Nipple complications | n = 69 (%) |
| Nipple areolar complex sloughing | 6 (8.7) |
| Nipple areolar complex loss | 1 (1.5) |
| Nipple hypopigmentation | 4 (5.8) |
| Revision procedures | n = 72 (%) |
| Return to OR | 3 (4.2) |
| Revision performed in office | 1 (1.4) |
IR, interventional radiology; OR, operating room.
Inferential Analysis of Complications and Patient Characteristics
| Hematoma | Seroma | Delayed Healing | Infection | Return to Operating Room | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | |||||||||||
| Age | 1.07 | –0.96 | 1.18 | 0.285 | 0.82 | –0.52 | 1.12 | 0.193 | 0.89 | –0.48 | 1.30 | 0.572 | 1.22 | –0.99 | 1.45 | 0.081 | 1.06 | –0.02 | 2.10 | 0.308 |
| BMI | 1.15 | –0.99 | 1.31 | 0.08 | 0.87 | –0.62 | 1.12 | 0.282 | 1.41 | –0.88 | 1.94 | 0.205 | 0.95 | –0.62 | 1.28 | 0.792 | 1.07 | –0.93 | 1.21 | 0.33 |
| Binding time | 1.03 | –0.97 | 1.09 | 0.35 | 1.04 | –0.97 | 1.11 | 0.265 | 0.7 | –0.13 | 1.27 | 0.222 | ||||||||
| Testosterone duration | 1.04 | –0.98 | 1.10 | 0.25 | 0.96 | –0.83 | 1.09 | 0.504 | 1.04 | –0.95 | 1.13 | 0.387 | 1.05 | –0.99 | 1.11 | 0.118 | ||||
| Weight resected | 1 | –1.00 | 1.00 | 0.944 | 0.99 | –0.99 | 0.99 | 0.34 | 1 | –1.00 | 1.00 | 0.105 | 1 | –1.00 | 1.00 | 0.949 | 0.99 | –0.99 | 0.99 | 0.351 |
| Operative date | 0.99 | –0.99 | 0.99 | 0.06 | 1 | –1 | 1 | 0.118 | 1 | –1 | 1 | 0.645 | 1 | –1 | 1 | 0.108 | – | |||
| Operative time | 0.97 | –0.94 | 1.00 | 0.822 | 0.99 | –0.96 | 1.02 | 0.809 | 0.99 | –0.93 | 1.05 | 0.741 | 0.98 | –0.92 | 1.04 | 0.515 | 1 | –0.97 | 1.03 | 0.515 |
| Nicotine use | 0.3 | 0.862 | 3.22 | 0.2 | 0.43 | 0.808 | 1.74 | 0.418 | ||||||||||||
| Marijuana use | 0.4 | 0.526 | 0.4 | 0.526 | 0.13 | 0.719 | 0.13 | 0.719 | 0.53 | 0.465 | ||||||||||
| Preop binding | 0.35 | 0.555 | 0.34 | 0.555 | 0.46 | 0.499 | 0.98 | 0.321 | ||||||||||||
| Testosterone use | 0.77 | 0.38 | 0.77 | 0.38 | 0.25 | 0.618 | 0.25 | 0.618 | 1.12 | 0.291 | ||||||||||
| Psychiatric comorbidity | 0.02 | 0.884 | 2.07 | 0.15 | 2.42 | 0.12 | 2.42 | 0.12 | 0.04 | 0.85 | ||||||||||
NC, no combination.
Bold values indicate a statistically significant finding.